As the world’s population ages, health experts are bracing for higher rates of age-related diseases, including Alzheimer’s. Finding new ways to diagnose the condition is more of a priority than ever, ...
As of 2023, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer’s disease, according to the Alzheimer’s Association. With that number projected to more than double to 13.8 ...
Roche has received US Food and Drug Administration (FDA) 510(k) clearance for additional cerebrospinal fluid (CSF) assays for Alzheimer’s disease (AD), supporting timely diagnosis and treatment ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new ...
Roche is on a roll: For the second time in less than a year, the company has scored FDA clearance for a pair of assays that can be used together to help spot signs of Alzheimer’s disease. The duo ...
In a recent study published in the journal Nature Medicine, a group of researchers assessed if a precise blood test matches or surpasses traditional cerebrospinal fluid (CSF) tests in detecting ...
A genomic test developed at UC San Francisco to rapidly detect almost any kind of pathogen – virus, bacteria, fungus or parasite – has proved successful after a decade of use. The test has the ...
This article was produced in partnership with the Davos Alzheimer’s Collaborative by Scientific American Custom Media, a division separate from the magazine’s board of editors. Henry, a carpenter in ...
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback